Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 2/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13910163 | 1.00 | ESR2 (0.38) | ESR2BRD4TSHRMAPT | |
| SCHEMBL2461 | 0.82 | — | — | |
| SCHEMBL21775731 | 0.82 | OPRK1 (0.34) | — | |
| SCHEMBL102654 | 0.80 | APLNR (0.35) | ESR2TSHR | |
| SCHEMBL19862576 | 0.80 | APLNR (0.35) | ESR2TSHR | |
| SCHEMBL24197652 | 0.79 | ESR2 (0.50) | ESR2BRD4 | |
| SCHEMBL240852 | 0.79 | ESR2 (0.50) | ESR2BRD4 | |
| SCHEMBL5733 | 0.79 | — | — | |
| SCHEMBL13223460 | 0.77 | ESR2 (0.42) | ESR2BRD4 | |
| SCHEMBL2702409 | 0.77 | ESR2 (0.42) | ESR2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170002014-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA AMERICA, INC. | 2017-01-05 | — | — | US | disclosed |
| EP-1355732-A4 | MONOLITH LOOP REACTORS | CORNING INC (US) | 2006-02-08 | — | — | EP | disclosed |
| US-6790417-B2 | COMPRISES FIXED HONEYCOMB CATALYST POSITIONED AS BYPASS WITHIN AGITATED CIRCULATION | CORNING INCORPORATED | 2004-09-14 | — | — | US | disclosed |
| EP-1355732-A1 | MONOLITH LOOP REACTORS | CORNING INCORPORATED (US) | 2003-10-29 | — | — | EP | disclosed |
| WO-2002051534-A1 | MONOLITH LOOP REACTORS | CORNING INCORPORATED (US) | 2002-07-04 | — | — | WO | disclosed |
| US-20020081254-A1 | Comprises fixed honeycomb catalyst positioned as bypass within agitated circulation | CORNING INCORPORATED | 2002-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170002014-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | ESR2 2182/4885BRD4 865/4885TSHR 956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.